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Abstract
The presence of endoleaks remains one of the main drawbacks of endovascular repair of abdominal aortic aneurysms
leading to the increase of the size of the aneurysmal sac and in most of the cases to repeated interventions. A variety
of devices and percutaneous techniques have been developed so far to prevent and treat this phenomenon, including
sealing of the aneurysmal sac, endovascular embolisation, and direct sac puncture. The aim of this review is to analyse
the indications, the effectiveness, and the future perspectives for the prevention and treatment of endoleaks after
endovascular repair of abdominal aortic aneurysms.
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Key points
 The detection rate of endoleaks depends on the
imaging modalities used
 Only a small percentage of endoleaks will require
re-intervention
 Treatment may include both endovascular or
percutaneous route
Introduction
The endovascular aortic repair (EVAR) of abdominal
aortic aneurysms was first described nearly three decades
ago and has offered a crucial management shift of patients
with aortic disease, particularly when open repair was not
an option [1–3].
A variety of EVAR devices were developed over the
years offering a range of outcomes. There has been a
substantial evolution in design and technology, from the
initial tube grafts to the custom-made fenestrated and
branched devices that are used today. EVAR has offered
some benefits over the traditional open surgical repair;
however, there is a cost to pay and this is mainly the
need of closer patient follow-up and sometimes the
necessity of re-interventions [4–9]. Follow-up is required
to assess growth of the aneurysm sac, device migration,
blockage, or infection. The most common reason for re-
intervention is the increase of the aneurysmal sac due
persistence of flow, a phenomenon otherwise known as
“endoleak” [4–9]. The purpose of this review article is to
illustrate the various types of endoleaks and to describe
what the current status of percutaneous management is.
Classification of endoleaks
Endoleaks are classified into five types (I–V). Type I
occurs due to incomplete proximal (Ia) or distal (Ib) seal.
This could be due to either inappropriate device selection,
incorrect graft deployment, or disease progression [10].
Type Ia may also appear when chimneys are used and are
known as “gutter endoleaks” [11, 12]. Type II occurs due
to sac centripetal reperfusion via side branches (lumbar
arteries, inferior mesenteric artery, accessory renal arte-
ries) with inverted flow. Type III is a result of dislodge-
ment of the various graft components. Type IV occurs due
to increased porosity of the graft material. Type V (also
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known as “endotension”) is the type of endoleak that can-
not be classified in any of the other categories.
Incidence
It is not easy to define the precise incidence of endoleaks
from the existing data in the literature. The evidence-
based practice centre of the Mayo Clinic has published
in 2017 a systematic review and meta-regression analysis
evaluating surveillance outcomes after EVAR for AAA
including 6 meta-analyses and 52 observational studies
[13]. The authors confirmed that an endoleak incidence
rate is subject to the type of imaging modality used for
their detection and reported that a combined approach
of DUS, non-contrast-enhanced CT, and MRI offered
the highest endoleak detection rate at 12, 24, 36, and 48
months of 35%, 46%, 51%, and 92%, respectively. At 60
months, the highest detection rate (91%) was observed
using a combined approach of DUS, CTA, and MRI.
However, most of the centres adopt the use of CTA with
delayed images as the “gold standard” as it is the most
cost-effective single modality for endoleak detection.
Operator experience and appropriate sizing decreased
the incidence of type I (both a and b) endoleaks with the
use of conventional devices over the years. However, the
incidence of type Ia is still high when chimneys are used,
reaching sometimes even 30% [14]. Type II endoleaks re-
main stable over the years in terms of incidence and
have been reported around 10% for emergency EVARs
and around 20% after elective repairs [15]. Types III–V
endoleaks have been reported with lower incidence, in
the region of 1–3% [16].
Symptoms and management
Understanding the aforementioned different pathophysi-
ology mechanisms that lead to the various types of endo-
leaks permits to distinguish the high- and low-flow nature,
which impacts on the requirement or not of repeated inter-
vention and correction. In particular, high-flow endoleaks
could lead to the rupture of the aneurysmal sac and may
be associated with symptoms like lumbar pain, or even
hypotension and tachycardia due to hypovolemic shock
[17]. On the other hand, type II endoleaks due to their
pathophysiology mechanism of onset are classified as low
flow. This is because the sac reperfusion occurs via col-
lateral circulation arising with inverted flow from the
periphery towards the aneurysm sac. In these cases, the
sac is exposed to a low-pressure flow that may lead to
sac enlargement over time. The evolution can be slow
and the endoleak can either be managed conservatively
[18, 19] or lead to sac expansion over 5 mm in a year
in which case treatment will be deemed necessary
[20–23]. According to the type of endoleak, different
approaches may be followed [24].
Type I endoleaks
Type Ia may have an immediate onset after graft deploy-
ment that offers the option to treat it in the same ses-
sion. Type Ib usually has a late onset that would require
late re-intervention only in case of sac growth.
Intra-procedure detection
If a type Ia is detected immediately after graft deploy-
ment, the first approach is to expand further the neck of
the graft with a moulding balloon. If the effect of the
balloon is not satisfactory or if the type Ia is a result of a
low graft deployment then the deployment of a cuff
needs to be considered (Fig. 1). Cuffs are available for
most of the devices; however, if a cuff is not available
and the moulding balloon does not appear to work, then
the use of a bare stent (Palmaz stent, Cordis Inc) that
may expand to the desired diameter needs to be consid-
ered. The long-term results of the use of Palmaz stents
in treating intra-procedural type Ia endoleak, in patients
whom proximal stent graft cuff implantation was not
feasible, has been published by Abdulrasak et al. [25]
They reported that between 1998 and 2012, 125 patients
were treated endovascularly in both elective and emer-
gency settings (83 elective and 42 emergencies) demon-
strating a primary and assisted freedom from type Ia
endoleak at 5 years of 84 ± 4% and 89 ± 3%, respectively
(elective vs emergency cases). Recently, endoanchors
have been introduced that may be used to fix further the
graft to the aortic wall particularly when the type Ia is
due to a short neck [26] (Fig. 2).
Late detection
If the type Ia is detected in one of the follow-up scans,
then all the abovementioned approaches may be equally
used according to the anatomy and the operator’s prefer-
ences. However, if there is disease progression with neck
expansion and no suitable anatomy for a cuff, a Palmaz
stent or the use of endoanchors then extension of the graft
in the suprarenal and visceral segment is required with
the use of more complex chimney/periscope techniques
or the use of a fenestrated or branched cuff. The use of
chimneys and periscopes are rescuing endovascular tech-
niques that employ the shelf stent grafts to extend the
proximal or distal landing zones. Stent grafts are deployed
parallel to an aortic extension in order to preserve flow
within the aortic visceral vessel branches. Chimneys are
performed to divert flow from the aortic lumen towards
the branches in a standard anatomy (proximally-distally),
whereas periscopes divert flow from the aortic lumen to-
wards the branches in a reversed direction. Montelione et
al. [27] reported 12 years experience in 24 patients pre-
senting a type Ia endoleak after a previous endovascular
aneurysm repair (EVAR) treated with chimney and/or
periscope grafts. They demonstrated a technical success of
Orgera et al. Insights into Imaging           (2019) 10:91 Page 2 of 10
96%, with effective intraoperative revascularisation of all
target vessels; moreover an estimated survival at 12, 24,
and 36months of 83% and estimated snorkel/chimney pa-
tency at the same intervals of 94%. The authors demon-
strated aneurysm sac shrinkage during a mean follow-up
of 23.4 ± 29months. Mean maximal aneurysm sac diam-
eter decreased from 88 ± 26 to 85 ± 33mm (p = 0.49) over
the course of the follow-up. Aneurysm sac diameter
remained stable or decreased in 21 (87%) patients; the
other 3 had sac diameter increases > 5mm, one of which
was related to a recurrent type Ia endoleak.
In the case of type Ib endoleaks, embolisation of the
ipsilateral internal iliac artery and distal graft extension
is usually the most straightforward solution [28, 29].
Type II endoleaks
Prevention
Several studies have examined the effectiveness of pre-
operative embolisation of branch vessels for the prevention
of type II endoleaks [30–32]. Alerci et al. [31] evaluated the
embolisation of large lumbar arteries prior to EVAR on
124 patients. The rate of type II endoleaks was significantly
lower in the embolisation group (3.6% vs 47.8%, p < 0.001)
after a mean clinical follow-up of 60.5 ± 34.1months
(range 1–144). Piazza et al. [32] reported similar results
and also demonstrated that patients who underwent pre-
operative embolisation experience faster sac shrinkage and
that the only independent predictor of a type II endoleak
occurrence is preoperative aneurysm sac volume > 125
cm3. A meta-analysis by Biancari et al. [33] demonstrated a
pooled rate of type II endoleak after IMA embolisation of
19.9% versus 41.4% in patients without IMA embolisation.
However, despite this different prevalence of endoleaks,
the authors conclude that since treatment for type II endo-
leaks is needed in less than 20% of cases and this complica-
tion can be treated successfully in 60–70% of cases
resulting in an aneurysm rupture risk of 0.9%, embolisation
of patent IMA may be not of overall benefit to patients
undergoing EVAR. Nevertheless, there are groups that still
suggest that IMA embolisation may be a preventive meas-
ure particularly for arteries with a diameter > 3mm [34].
Furthermore, the role of intra-procedural embolisation
of the aneurysmal sac with thrombin and gelfoam slurry
has been investigated, in limited series, demonstrating a
trend towards lower rate of type II endoleaks when com-
pared with the literature median rate [35]. Zanchetta et al.
[36], in a prospective, nonrandomised pilot study used fi-
brin glue aneurysm sac embolisation at the time of EVAR
in 84 patients and demonstrated a low rate of delayed type
II endoleak and a statistically significant decrease in the
Fig. 1 a Coronary reconstruction of CTA scan confirming deployment of the graft in a caudal position led to sac expansion in the follow-up
period. b Angiogram confirmed the low graft position. c A cuff was deployed in an immediate infrarenal position to prevent any further
sac expansion
Fig. 2 Endoanchors were employed to fix the proximal graft given the short (< 10mm) neck. a, b Fluoroscopic picture showing the delivery of
the anchors. c Angiogram confirming the good apposition of the graft after the deployment of four endoanchors
Orgera et al. Insights into Imaging           (2019) 10:91 Page 3 of 10
maximum transverse aneurysm diameter at follow-up.
Muthu et al. [37] in a study performed in 2007 where
patients that received IMA embolisation combined with
intraprocedural thrombin injection in 69 consecutive
patients that underwent elective EVAR showed a trend of
endoleak reduction; however, no statistically significant
difference was reached (26% compared with 14%) and the
authors concluded that ongoing research into means to
prevent lumbar endoleaks is required. Even though there
is a variety of studies available, there is still not enough
evidence to support routine embolisation of the IMA or the
lumbar arteries or intraprocedural thrombin injection
prior to routine EVAR and this remains an operator’s
preference [38].
To avoid the doubt of preoperative embolisation for
the prevention of type II endoleaks, the Nellix EVAS
device (Endologics) was developed aiming to “seal” the
sac instead of blocking the centripetal flow. The Nellix
system comprises two 10-mm balloon expandable
chromium-cobalt stent grafts that are inserted into the
aorta in a “double-barrel” conformation. A bag is
attached to each of the stent grafts and is filled with a
polymer during insertion in order to conform accord-
ing to the anatomical shape of the flow component of
the aneurysmal sac [39]. By filling the aortic lumen,
the endobags eliminate the space in the sac and limit
the possibility of flow towards it. Therefore, when Nel-
lix was launched few years ago, there was a high ex-
pectation on limiting the rate of type II endoleaks.
Nevertheless, the device did not perform at the stan-
dards that it was initially expected, probably because
in most of the cases it was used outside the instruc-
tions for use (IFU) [40–43]. Specifically, the IFU
instructed aortic proximal neck diameter range of 18
to 28 mm, minimum aortic proximal neck length ≥ 10
mm, proximal aortic neck angulation of ≤ 60°, aortic
aneurysm with a blood lumen diameter ≤ 70 mm, ratio
of maximum aortic aneurysm diameter to maximum
aortic blood lumen diameter < 1.4, and distal iliac ar-
tery seal zone with length of ≥10 mm and diameter
range of 9 to 25 mm. When the device was used within
IFU, like in the series of Carpenter et al. [44], it per-
formed much better. However, given the erroneous
use, type Ia endoleaks were developed that were im-
possible to control, leading to graft separation and sac
expansion (Fig. 3). Most of the devices were explanted
and the graft lost the European Conformity mark in
January 2019.
Fig. 3 a Coronary reconstruction of a CT scan showing the satisfactory deployment of a Nellix device with lack of separation of the grafts. b
Transverse CT scan confirming the sac size after deployment. c, d Follow-up CT 2 years later shows separation of the grafts and sac expansion.
This is a result of a subtle type Ia endoleak between the two grafts.
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Endovascular treatment
Regarding the endovascular treatment of type II endoleaks,
the aim is to reach the aneurysmal sac and block the feed-
ing vessels with embolisation material in order to control
the sac growth [45]. The approach differs according to the
collateral pathways involved in the sac reperfusion. The
focus of treatment is to seal all access to the sac and if pos-
sible to directly embolise the sac to avoid recurrence. If the
endoleak is supplied by the IMA, a retrograde approach
from the superior mesenteric artery and the Riolan arcade
will be required (Fig. 4) [46]. In the case of supply via the
lumbar arteries, catheterisation via the ileo-lumbar anasto-
moses that take origin from the ipsilateral internal iliac
artery should be performed. The enlargement of this colla-
teral pathway may allow the navigation with a microcath-
eter permitting super selective catheterisation of the
feeding lumbar arteries. Ribè et al. [47] reported a technical
success of 100% and no endoleak recurrence via the treated
collateral pathways till 19months of follow-up employing
an Onyx liquid embolic agent.
Percutaneous treatment
Another way of treating the type II endoleaks is via direct
percutaneous sac access under ultrasound (US), computed
tomography (CT), or digital subtraction angiography
(DSA) guidance (Fig. 5).
Baum et al. [48] described the first experience with
translumbar embolisation in literature of type II endoleaks
after endovascular repair of abdominal aortic aneurysms.
Translumbar paraspinal left-side access with a patient in
the prone position is the most common generally per-
formed approach to avoid the inferior vena cava (IVC)
while the choice of transabdominal is preferred when an
endoleak sac is located or extended anteriorly from the
aneurysm sac. Stavropoulos et al. [49] described a prone
right-sided percutaneous transcaval approach in order to
manage either position of the endoleak or interposed
bowel and organs.
The direct access should be performed with a micro
puncture access set and guided by ultrasound, CT, or
DSA depending on either the anatomy or the operator’s
preference. Van Bindsbergen et al. [50] described a tech-
nique for real-time three-dimensional needle guidance
using cone-beam CT co-registered to fluoroscopy, which
can potentially facilitate treatment of small a nidus
decreasing radiation and contrast doses compared with
traditional methods. Once the nidus is accessed, the nee-
dle is exchanged over a guidewire for a vascular sheath
and a 4Fr or 5Fr selective catheter. Contrast media is
injected to obtain an endoleak-o-gram to define the size
of the nidus and the location of the inflow and outflow
arteries. Embolisation is performed until the nidus is
Fig. 4 Percutaneous embolisation for type II endoleak. a Delayed CTA reveals the presence a type II endoleak (arrow). b .Angiogram confirming
the access via the Riolan arcade to the IMA. c Embolisation with Onyx and (d) satisfactory angiographic result
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occluded. The feeding vessels should also be embolised
if feasible, but this may be problematic particularly in
the case of lumbar arteries due to their unfavourable
anatomy as U-turn shape to extend posteriorly [51].
Furthermore, an alternative access route to reach the
aneurysmal sac has been reported via the inferior vena
cava as mentioned [52–54]. In these cases, the
aneurysmal sac is accessed through the inferior vena
cava thanks to the employment of a transhepatic shunt
access needle set in order to puncture the sac. Then, the
microcatheter is advanced within the sac and the embol-
isation performed. Scali et al. [52] reported experience
on transcaval embolisation with coil placement and se-
lective thrombin injection in six patients with 100%
technical success and no postoperative complications. In
one patient, repeated treatment was required at follow-
up of 8.1 months. Giles et al. [54] reported a larger ex-
perience in 26 patents who underwent transcaval coil
embolisation of the aneurysm sac at a mean of 4.2 ± 4
years after initial endovascular aneurysm repair. There
were no procedural adverse events and re-intervention
was required in five cases.
A new very interesting percutaneous approach has
been reported by Ogawa et al. [55] who performed a
transpedicular direct puncture using an isocentre punc-
ture method: an isocentre marker was placed at a site
corresponding to the aneurysm sac on fluoroscopy in
two directions (frontal and lateral views); then, a verteb-
roplasty needle was inserted tangentially to the marker
under fluoroscopy and advanced to the anterior wall of
the vertebral body. Finally a 20 cm-length, 20G needle
was inserted through the outer needle of the 13G needle
and advanced to the marker.
The embolic agent options include mechanical devices
and liquids, used in combination or alone, with a choice
of an embolic material tailored to the patient’s anatomy
and operator preference. There are no conclusive data
on the advantages or disadvantages of the different em-
bolic agents to date, even if high rates of endoleak recur-
rence (50 %) have been reported in small case series
with the use of thrombin as the predominant embolic
agent [54], and it seems its use should be avoided.
Some complications of the direct approach have been
reported to date, the most clinically significant is a pul-
monary embolus secondary to extravasation of the glue
in the IVC, stent puncture leading to the development
of a type III endoleak [54] and bowel ischemia [52].
Comparison of endovascular and percutaneous
management
A debate in the literature exists between the use of
DSPE and transarterial embolisation (TAE) but there is
no consensus on which is the most effective or first-line
approach for type II endoleaks. Even though there are
several retrospective series of patients comparing the
two techniques, there is no prospective randomised
comparison of TAE versus DSPE. Baum et al. [48] pub-
lished the first study in 2002 where 20 patients under-
went TAE of the IMA and 13 patients underwent direct
translumbar embolisation. Over the follow-up period of
254 days, 16 out of the 20 transarterial embolisation, pa-
tients required re-intervention due to recanalisation of
the initially embolised vessels. Most of the DSPE proce-
dures however were successful with only one recurrence.
The authors report a 92% success rate after DSPE using
coils, compared with an 80% failure rate of transarterial
coil embolisation of the feeding vessels. They concluded
that DSPE should be the technique of choice for type II
endoleaks. This was a milestone study that triggered the
development of further percutaneous techniques.
Sidloff et al. [18] in a systematic review reported an
overall failure rate of 37.5 % for TAE compared with a
19% for DSPE; however, it is important to highlight that
in many studies, the translumbar approach represents a
“bail-out” of the transarterial one and the results would
probably have been different if this was the initial ap-
proach. On that note, Uthoff et al. [56] conducted a sin-
gle-centre retrospective analysis of 19 type II endoleaks
treated via translumbar approach, and they demon-
strated an initial technical success rate of 88%; however,
Fig. 5 a Direct puncture of the sac under CT and fluoroscopic guidance. Angiogram confirms the presence of the small nidus and the feeding
vessel. b CT scan during embolisation with Onyx
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in half of these patients recurrence occurred after 39
months of follow-up and in two-thirds of them a second-
ary procedure was necessary. In a paper of 2016, Yang et
al. [57] reported on twenty-three type II endoleak patients
similar sac occlusion effectiveness, between direct sac
puncture and transarterial embolisation. The median fol-
low-up was 21.8months. Direct access was considered as
the preferred approach due to shorter fluoroscopic and
procedural times. The studies from the literature compar-
ing DSPE and TAE are shown in Table 1.
Types III, IV, and V endoleaks
Type III
Chaikof et al. [58] classified first type III endoleaks in
2002 in “Reporting standards for endovascular aortic
aneurysm repair”. They may occur either due to discon-
nection of components of the modular endograft system
(IIIa) or a defect in the stent-covering graft fabric (IIIb).
Type III b endoleaks are further stratified with respect
to the extent of fabric disruption as major (> 2 mm) or
minor (< 2 mm). Incidence of type III endoleaks has
been reported from 1 to 11% [59]. Also based on the
complexity of the anatomy, type IIIa endoleak could be
classified as simple and complex. Improper seal,
inadequate overlap of modular components, and distal
component migration are considered as simple type III
endoleaks, whereas major component dislocation includ-
ing total mal-alignment results in complex type IIIa
endoleaks. With the advent of more complex fenestrated
EVAR and TEVAR procedures, the total number of
junctions in endografts has increased with the possibility
of a corresponding increase in the incidence of type III
endoleaks. Type III endoleaks arising from side branches
are a special concern after fenestrated endografting, with
reported rates of 0 to 6.8% [60].
Treatment consists in either realigning the dislodged
stent graft parts or advancing another covered stent in
the dislodged branches/ fenestrations in the b-EVAR/ f-
EVAR case.
Type IV
In patients who underwent EVAR repair, type IV endo-
leaks are very rare [61, 62]. Espinosa et al. reported a
prevalence of this type of endoleak as 0.3% [63]. Forbes
et al. reported the conservative treatment as sufficient,
in the case of type IV endoleak. Furthermore, in longer
follow-up observation, a type IV endoleak was not the
cause of the aneurysm re-supply in open surgery [64]
and some clinicians think that type IV endoleaks should
be classified as a type V endoleak.
Type IV endoleaks are even more rare with the new-
generation stent grafts. In such cases, usually, the best
management is surgical conversion with graft explant-
ation [65, 66].
Type V endoleaks
Type V endoleaks are a result of “endotension”. With this
term is defined the aneurysm sac growth without any de-
tectable endoleak and is a result of increased pressure
within the aneurysm sac (Fig. 6) [67]. This may be due to
such slow blood flow that it is below the sensitivity limits
for detection on current imaging methods. This kind of
endoleak seems to be more common with expanded poly-
tetrafluoroethylene (ePTFE) fabric grafts rather than poly-
ester covered ones. New-generation ePTFE grafts include
a second layer of low permeability ePTFE to decrease this
risk [68]. No studies have shown an increased risk of
aneurysm rupture among patients with endotension [69,
70]. However, the current view regarding type V manage-
ment is that when sac growth of more than > 8mm
occurs, then some form of re-intervention is required [71,
72]. Nevertheless, further studies are required to demystify
this phenomenon and condition and delineate the appro-
priate management.
Table 1 Studies in the literature that compare the direct sac with the endovascular approach for the treatment of Type II endoleaks.
Technical success*: immediate exclusion of the sac at the first control. Clinical success**: freedom from endoleak recurrence at the
follow-up. DSPE, direct sac puncture embolisation; TAE, transarterial embolisation
Study No. Mean follow-up time Technical success* (%) Clinical success** (%)
Baum et al. [48] 20 TAE 254 days 90 20
13 DSPE 254 days 100 92
Stavropoulos et al. [49] 23 TAE 17.3 months 95.7 78.3
62 DSPE 20.2 months 100 72.6
Nevala et al. [74] 10 TAE 4.5 ± 2.3 years 40 20
4 DSPE 4.5 ± 2.3 years 100 75
Massis et al. [75] 65 TAE 15 weeks 58 76
36 DSPE 15 weeks 100 59
Yang et al. [57] 23 DSPE 21.8 months 100 64
81 57
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Future perspectives
Considering the impact that endoleak prevention and
treatment have for health economics, there is continuous
research on the field with a prediction for an exponential
increase in the next 5 years. The main areas that will be
developed are the following:
– Imaging modalities, mainly for the early detection
of and characterisation endoleaks, aiming for
radiation-free modalities like contrast-enhanced
ultrasound (CEUS) and magnetic resonance imaging.
The version 1.3 of the study on the early detection
of endoleaks with CEUS (NCT02688751) is recently
completed. The primary outcome is to assess the
ability of CEUS to detect type I/III endoleaks on
CEUS as defined by presence/absence on time-
resolved CTA. The secondary outcome is the
detection of type II endoleaks and the ability of
CEUS to predict the likelihood of a secondary
intervention. The study has also assessed healthcare
costs related to each imaging modality, considering
that EVAR follow-up carries an important economic
impact. The results have not been made public yet.
Radiation reduction can also be achieved with dual-en-
ergy CT that acquires two different photon spectra in a
single acquisition. It can be used to detect endoleaks
with good accuracy and at a reduced radiation exposure
and some preliminary data is already available [73].
– Biomarkers that would predict the aneurysm
evolution. The best example is the matrix
metalloproteinase (MMP) activity that has been
associated with the process of aneurysm
development. In essence, if there is a lack of balance
between the MMP and its inhibitors, degeneration
of the aortic wall is induced. It was previously
proved that the serum level of MMP-9 is
significantly higher in patients with abdominal aortic
aneurysm and in patients with inadequate aneurysm
exclusion after EVAR. A multicentre trial of serum
levels of MMP-9 as a biomarker of endoleak
(NCT01965717) has recently been completed. The
aim of the study was to establish the correlation of
MMP-9 with specific types of endoleaks and the
requirement for re-intervention. The results have
not been made public yet.
– Endostaples have offered satisfactory results after the
completion of the pivotal study of the Aptus
Endovascular AAA Repair System (NCT00507559).
The ANCHOR (Aneurysm Treatment Using the Heli-
FX Aortic Securement System Global Registry) study is
currently recruiting patients (NCT01534819) aiming
for a primary completion date in 2020. The primary
outcome measures are the prevention of graft
migration and the treatment of Type Ia endoleak.
– Navigation systems in CT offer more accurate needle
placement and as the number of direct sac interventions
will increase accurate needle placement under CT
fluoroscopy will be necessary. The Endoleak Repair
Guided by Navigation Technology study
(NCT01843322) is a small study of 27 patients that is
recently completed and is aiming to delineate whether
the treatment of type II endoleaks can be improved by
adding navigation technology in terms of precision and
reduction of radiation exposure.
– Novel polymers will be developed after the Nellix
system, regardless of the fact that the results until
today have not been as expected. The novel ANEUFIX
system in the treatment of endoleaks is assessed in a
feasibility study (NCT02487290). The study is a non-
randomised, multi-centre safety and feasibility trial of
Aneufix ACP-T5 to treat patients with isolated type II
endoleaks in the presence of a non-shrinking AAA sac
following an EVAR procedure; however, it has only
recruited 4 patients at the moment.
Conclusion
We may conclude that as the treatment options for
endovascular repair of abdominal aortic aneurysms and
the complexity of devices increase, there will be an
increased necessity of prevention and management of
endoleaks. Radiology is crucial in the management of
such a phenomenon and needs to offer a number of
solutions in the endoleak prevention and management.
Fig. 6 a-c CTA scan showing continuous expansion of the aneurysmal sac after initial repair for rupture. The expansion occurred over three years
reaching a size of nearly 10 cm but without any evidence of an endoleak. It was considered as a result of “endotension”
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